Business NewsPR NewsWire • Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan

Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan

Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan

CAMBRIDGE, Mass., May 9, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. (Taipei, Taiwan) today announced the signing of an agreement under which Merrimack has acquired the rights to develop and commercialize MM-398 (aka PEP02) in Europe and Asia.   (Logo: http://pho

View More : http://www.prnewswire.com/news-releases/merrimack-pharmaceuticals-acquires-european-and-asian-rights-to-mm-398-nanolipos...
Releted News by prnewswire
Inmarsat plc Interim Management Statement
Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan
Li3 Energy Signs MOU With One of the World's Largest Steel Manufacturers for Access to Lithium
Moofwd Unveils Mooestro m-Learning Solution